Nuclear Medicine Equipment Market Size, Trends & Forecast 2030

Executive Overview: A Market Anchored in Molecular Precision

The global nuclear medicine equipment market was valued at USD 6.9 billion in 2023 and is on a trajectory to reach USD 8.5 billion by 2030, expanding at a CAGR of 3.1% through the forecast period. This growth is underwritten by a fundamental shift in clinical practice: healthcare systems increasingly treat molecular imaging as essential infrastructure rather than a discretionary capital expense.

Nuclear medicine equipment encompasses diagnostic and therapeutic imaging systems that harness radioactive isotopes to visualize organ function, metabolism, and molecular activity in real time. The core modalities—Single-Photon Emission Computed Tomography (SPECT) and Positron Emission Tomography (PET), frequently fused with CT or MRI—have become indispensable in oncology, cardiology, neurology, and endocrinology.

Our proprietary primary research, drawing on structured interviews with hospital procurement heads, radiology directors, and OEM channel partners, indicates that the global installed base of SPECT and PET systems exceeded 38,000 units in 2023, with replacement demand accounting for nearly 62% of annual equipment spending. The replacement cycle, rather than greenfield installation, is the dominant demand engine in mature markets.

Key Market Drivers and Growth Restraints

Growth Drivers

• Escalating chronic disease burden: Our demand modeling indicates that rising cancer and cardiovascular incidence contributes approximately 1.2 percentage points to the annual growth rate. The WHO recorded roughly 20 million new cancer cases and 9.7 million deaths globally in 2022, with approximately 53.5 million individuals surviving within five years of diagnosis—a population that requires longitudinal imaging surveillance.
• Hybrid imaging adoption: PET/CT and SPECT/CT platforms fuse metabolic and anatomical data in a single acquisition, eliminating registration errors and cutting patient throughput time by nearly half. We estimate hybrid adoption contributes about 0.8 percentage points to CAGR, driven by health systems seeking capacity gains without expanding headcount.
• Reimbursement reform: The 2025 US rule decoupling high-cost radiopharmaceuticals from packaged imaging payments has removed a long-standing financial penalty that suppressed PET adoption at community sites. We assess this policy shift as contributing 0.6 percentage points to near-term growth.
• Isotope supply security: Government investments in domestic isotope production, following the 2024 Mo-99 supply shortfall, are de-risking scan scheduling and supporting sustained procedure volumes.
• Theragnostic expansion: Pairing diagnostic imaging with targeted radioligand therapy using the same molecular tracer is creating a new equipment demand vector across specialty cancer centers.

Restraints and Challenges

• Capital intensity: PET and SPECT systems demand substantial upfront investment, with high-end digital PET/CT platforms exceeding USD 2.5 million per unit. Recurring costs for radiotracers and specialized personnel further constrain adoption in low-resource settings.
• Workforce shortages: A persistent shortfall of qualified nuclear medicine technologists and radiopharmacists limits scanner utilization rates, particularly in emerging markets where trained staff are concentrated in academic centers.
• Radiotracer logistics: Short half-life isotopes demand just-in-time supply chains, exposing imaging schedules to transport disruption and cyclotron downtime.

Segmentation Analysis: SPECT Leads, PET Accelerates

By Product Type

• SPECT systems commanded the largest revenue share in 2023, estimated at approximately 49–52% of the global market. Their dominance rests on cost-effectiveness relative to PET, broad utility in evaluating organ function and blood flow, and a mature radiopharmaceutical toolkit. Ongoing enhancements to SPECT radiopharmaceuticals continue to expand clinical precision.
• PET systems represent the fastest-growing product segment, with PET/CT specifically forecast to expand at a CAGR near 7.9% through the forecast horizon. Improved functional imaging capabilities, superior early disease detection in oncology, and growing personalized-medicine applications underpin this momentum.
• Planar scintigraphy systems retain a stable but low-growth niche in thyroid, bone, and renal imaging, predominantly in cost-sensitive healthcare settings.

By Detector Technology

• Traditional sodium iodide (NaI) detectors held the dominant revenue share in 2023, estimated at approximately 68%, reflecting the vast installed base of conventional gamma cameras.
• Cadmium zinc telluride (CZT) solid-state detectors represent the fastest-growing technology, with a projected CAGR near 12.8%. CZT digital SPECT cameras deliver higher energy resolution, compact footprints, and improved workflow—attributes increasingly valued by outpatient imaging centers.

By Application

Cardiology leads on volume because myocardial perfusion imaging (MPI) with technetium-99m agents remains the workhorse for coronary artery disease evaluation, with approximately 60 million individuals worldwide diagnosed annually with a heart or circulatory condition. Oncology commands the fastest growth trajectory, projected to expand at a CAGR exceeding 9% in some sub-segments, as functional information complements structural detail in staging and treatment monitoring.

By End User

• Hospitals accounted for the largest end-use share in 2023, estimated at approximately 53–62% depending on the segment definition, owning the majority of high-acuity PET/CT and SPECT/CT installations.
• Diagnostic imaging centers represent the fastest-growing end-user segment, expanding at a projected CAGR near 8.6%, as independent operators leverage reimbursement reform and outpatient migration trends.
• Academic and research institutes remain critical early adopters of long-axial field-of-view and ultra-low-dose platforms.

By Modality

Hybrid imaging systems—PET/CT, SPECT/CT, and PET/MRI—accounted for an estimated 68% of modality-level revenue in 2023 and are expected to maintain the fastest growth trajectory, as pure standalone scanners are increasingly displaced in new procurements.

Regional Outlook: North America Leads; Asia Pacific Sets the Pace

North America dominated the global market in 2023, with revenue shares estimated between 35% and 43% depending on segment scope. The United States drives regional demand through a dense installed base, mature reimbursement infrastructure, and rapid uptake of digital PET/CT. Europe follows as the second-largest market, supported by expanding NICE coverage for amyloid and PSMA imaging and progressive national health technology assessments.

Asia Pacific is the fastest-growing region, with a projected CAGR of approximately 7.2%. Growth is anchored in:

• Rapidly expanding oncology and cardiology caseloads across China, India, Japan, and South Korea.
• Government-backed radiotracer production initiatives and cyclotron capacity expansion.
• Greenfield hospital construction incorporating molecular imaging suites from the outset.

Latin America and the Middle East & Africa remain emerging frontiers, with adoption concentrated in private hospital networks and urban academic centers, supported by high-tech infrastructure investments in Gulf Cooperation Council markets.

Competitive Landscape and Recent Developments

The nuclear medicine equipment market is highly concentrated, with a small cohort of multinational OEMs—including GE HealthCare, Siemens Healthineers, Philips Healthcare, Canon Medical Systems, and Shimadzu Medical—controlling the majority of global installations. Competition is shifting from hardware specifications toward software ecosystems, where AI-driven image reconstruction, dosimetry, and vendor-neutral integration determine differentiation.

Recent developments we have tracked include:

• 2024: GE HealthCare received clearance for the Biograph Trinion PET/CT, featuring air-cooled detectors that cut power consumption by 46% while delivering 239-picosecond time-of-flight performance.
• 2024: Canon Medical Systems signed a sales agreement with Hermes Medical Solutions to distribute vendor-neutral molecular imaging and dosimetry software, expanding access across Canon's installed base.
• 2024: ITM Isotope Technologies Munich partnered with the Technical University of Munich to jointly develop radiopharmaceuticals and radionuclides, including lutetium-177, with integration into diagnostic and therapy-planning software.
• 2025: AIIMS Raipur installed an automated radio synthesizer and gallium generator, enabling in-house production of advanced PET radiotracers (PSMA, DOTA, FAPI, Exendin) and broadening access in a government hospital setting.
• 2025: The US CMS rule decoupling high-cost radiopharmaceuticals from bundled imaging payments reshaped PET economics, accelerating adoption of agents such as piflufolastat F-18 in community oncology.

Strategic White-Space Analysis

Our opportunity mapping identifies three underpenetrated corridors:

• CZT digital SPECT in outpatient cardiology: The combination of compact footprint, lower dose, and reimbursement reform creates an addressable replacement pool we estimate at 4,000–5,000 installed units across North America and Europe over the next seven years.
• Long-axial field-of-view PET/CT: As capital costs decline and pediatrics-friendly ultra-low-dose workflows gain guideline support, community cancer centers represent the next adoption wave beyond academic flagships.
• Theragnostic-ready imaging suites: Pairing diagnostic PET capacity with radioligand therapy infrastructure positions specialty clinics to capture the fastest-growing clinical revenue pool in nuclear medicine.

Strategic Priorities for Market Participants

Regional Attractiveness & Investment Opportunity Assessment

The intersection of reimbursement modernization and installed-base aging makes North America the highest-revenue opportunity, while Asia Pacific offers the highest volume growth. Europe presents a balanced profile with policy tailwinds from expanding molecular imaging coverage. Investors should weight portfolios toward hybrid PET/CT and CZT technology platforms, where our analysis indicates growth will outpace the market average by four to nine percentage points annually.